Pharma BD Deal Intelligence

Eli Lilly and Company / ARMO BioSciences Inc.

2018 · Acquisition/Merger · $1.6B · Complete

Announcement Sentiment

Strongly positive

Outcome Score

Did not work — the deal failed to deliver.

Eli Lilly acquired ARMO BioSciences for approximately $1.6 billion ($50 per share) in an all-cash tender offer, gaining pegilodecakin (PEGylated IL-10), a Phase III immuno-oncology asset being studied across multiple solid tumor types.

Key facts

Announced May 10, 2018
Closed Jun 22, 2018
Deal value $1.6B
Deal type Acquisition/Merger
Therapeutic area Oncology
Indications Pancreatic Cancer, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma
Key assets pegilodecakin (AM0010)
Mechanism PEGylated IL-10 (interleukin-10) immune stimulant

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals